Company research
Metagenomi Therapeutics, Inc.
CIK 1785279Updated Sep 26, 2026
SecurityMGX · NASDAQ · equity
Name history
Metagenomi, Inc. · through Jan 12, 2026Metagenomi Technologies, LLC · through Jan 18, 2024
MGX price & chart
Loading TradingView…
NASDAQ:MGX on TradingView ↗About the company
Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel CRISPR gene-editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site specific deletion, insertion and correction.
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
Regulation FD Disclosure
Items 7.01, 9.01
4 filing
SCHEDULE 13G filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 221,103,000Source | 324,599,000Source | 364,842,000Source |
| Property, Plant and Equipment, NetUSD | 12,288,000Source | 17,740,000Source | 21,542,000Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 41,722,000Source | 27,386,000Source | 140,603,000Source |
| Assets, CurrentUSD | 165,538,000Source | 257,960,000Source | 278,273,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,434,000Source | 8,396,000Source | 4,640,000Source |
| Operating Lease, Right-of-Use AssetUSD | 35,094,000Source | 39,917,000Source | 43,611,000Source |
| Other Assets, NoncurrentUSD | 836,000Source | 287,000Source | 5,492,000Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 62,507,000Source | 89,742,000Source | 149,668,000Source |
| Commitments and ContingenciesUSD | — | 0Source | 0Source |
| Stockholders’ equity: | |||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 4,000Source | 4,000Source | 0Source |
| Additional Paid in CapitalUSD | 469,202,000Source | 457,146,000Source | 9,457,000Source |
| Retained Earnings (Accumulated Deficit)USD | -310,870,000Source | -223,002,000Source | -144,944,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 260,000Source | 709,000Source | -97,000Source |
| Stockholders' Equity Attributable to ParentUSD | 158,596,000Source | 234,857,000Source | -135,584,000Source |
| Liabilities and EquityUSD | 221,103,000Source | 324,599,000Source | 364,842,000Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 22,933,000Source | 37,309,000Source | 68,861,000Source |
| Operating Lease, Liability, CurrentUSD | 6,025,000Source | 5,592,000Source | 3,427,000Source |
| Accounts Payable, CurrentUSD | 1,489,000Source | 533,000Source | 1,791,000Source |
| Operating Lease, Liability, NoncurrentUSD | 34,632,000Source | 40,186,000Source | 44,802,000Source |
| Other Liabilities, NoncurrentUSD | 1,953,000Source | 2,010,000Source | 5,079,000Source |
| Additional Financial Items | |||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 160,800,000Source | 248,300,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -87,868,000Source | -78,058,000Source | -68,255,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 11,853,000Source | 16,204,000Source | 6,922,000Source |
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts ReceivableUSD | -952,000Source | -1,194,000Source | 2,451,000Source |
| Increase (Decrease) in Accounts PayableUSD | 1,054,000Source | -1,106,000Source | -84,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -88,892,000Source | -109,073,000Source | -91,409,000Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 103,529,000Source | -88,157,000Source | 45,734,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 574,000Source | 3,114,000Source | 9,814,000Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -356,000Source | 84,013,000Source | 1,012,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 14,281,000Source | -113,217,000Source | -44,663,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 46,915,000Source | 32,634,000Source | 145,851,000Source |
| Supplemental disclosure of cash flow information: | |||
| Income Taxes Paid, NetUSD | -2,238,000Source | 3,505,000Source | 2,250,000Source |
| Additional Financial Items | |||
| Share-based Payment Arrangement, ExpenseUSD | 11,853,000Source | 16,204,000Source | 6,922,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 160,800,000Source | 248,300,000Source | — |
| DepreciationUSD | 5,317,000Source | 5,407,000Source | 4,207,000Source |
| Gain (Loss) on Disposition of AssetsUSD | -502,000Source | — | — |
| General and Administrative ExpenseUSD | 26,790,000Source | 32,017,000Source | 28,845,000Source |
| Income Tax Expense (Benefit)USD | -58,000Source | -5,513,000Source | 8,027,000Source |
| Investment Income, InterestUSD | 9,470,000Source | 14,722,000Source | 15,468,000Source |
| Net Income (Loss) Attributable to ParentUSD | -87,868,000Source | -78,058,000Source | -68,255,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -87,868,000Source | -78,058,000Source | -68,255,000Source |
| Nonoperating Income (Expense)USD | 8,087,000Source | 5,330,000Source | 18,264,000Source |
| Operating ExpensesUSD | 121,223,000Source | 141,196,000Source | 123,248,000Source |
| Operating Lease, ExpenseUSD | 5,318,000Source | 4,644,000Source | 4,207,000Source |
| Other Nonoperating Income (Expense)USD | -91,000Source | -207,000Source | -74,000Source |
| Payments of Financing CostsUSD | 558,000Source | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total RevenueUSD | 25,210,000Source | 52,295,000Source | 44,756,000Source |
| Operating Income (Loss)USD | -96,013,000Source | -88,901,000Source | -78,492,000Source |
| Other Nonoperating Income (Expense)USD | -91,000Source | -207,000Source | -74,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -87,926,000Source | -83,571,000Source | -60,228,000Source |
| Income Tax Expense (Benefit)USD | -58,000Source | -5,513,000Source | 8,027,000Source |
| Net Income (Loss) Attributable to ParentUSD | -87,868,000Source | -78,058,000Source | -68,255,000Source |
| Earnings Per Share, BasicUSD per share | -2.36Source | -2.36Source | -20.05Source |
| Earnings Per Share, DilutedUSD per share | -2.36Source | -2.36Source | -20.05Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 37,251,050Source | 33,027,889Source | 3,404,585Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 37,251,050Source | 33,027,889Source | 3,404,585Source |
| Additional Financial Items | |||
| Current Income Tax Expense (Benefit)USD | -58,000Source | -5,513,000Source | 8,027,000Source |
| DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossPeriodIncreaseDecreaseUSD | 0Source | — | — |
| General and Administrative ExpenseUSD | 26,790,000Source | 32,017,000Source | 28,845,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -87,926,000Source | -83,571,000Source | -60,228,000Source |
| Investment Income, InterestUSD | 9,470,000Source | 14,722,000Source | 15,468,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -87,868,000Source | -78,058,000Source | -68,255,000Source |
| Nonoperating Income (Expense)USD | 8,087,000Source | 5,330,000Source | 18,264,000Source |
| Operating ExpensesUSD | 121,223,000Source | 141,196,000Source | 123,248,000Source |
| Operating Lease, ExpenseUSD | 5,318,000Source | 4,644,000Source | 4,207,000Source |
| Research and Development ExpenseUSD | 94,433,000Source | 109,179,000Source | 94,403,000Source |
Filing attachments
mgx-ex99_1.htm · 8-K · 2026-09-22
Precision gene editing designed to deliver durable, curative medicines Corporate Presentation September 2026 This presentation includes forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward looking statements, including statements regarding our cash runway, strategy and plans, industry environment, potential gr…
Read attachment ↗mgx-ex99_1.htm · 8-K · 2026-08-10
EX-99.1 2 mgx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in cash, cash equivalents, and available-for-sale marketable securities as of June 30, 2026, with runway anticipated to support operations through 4Q 2027 EMERYVILLE, Calif.…
Read attachment ↗mgx-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 mgx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results On track for regulatory submission of MGX-001 to advance global clinical program, including investigational new drug application (“IND”) in 4Q 2026 Publication in Nature Structural & Molecular Biology highlights potential of MG119-28, a proprietary compact CRISPR nuclease with enhanced genome editing efficiency $140.2 million in cash, cash equiv…
Read attachment ↗mgx-ex99_2.htm · 8-K · 2026-05-11
EX-99.2 3 mgx-ex99_2.htm EX-99.2 Precision gene editing designed to deliver durable, curative medicines Hemophilia A lead program | IND 2026 Corporate Presentation May 2026 This presentation includes forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward looking statements, including statements regarding ou…
Read attachment ↗